Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca; Pfizer
• Treatments: Avibactam; Ceftazidime; Cilastatin; Imipenem

Criteria

Inclusion Criteria:

• Acute pyelonephritis or other complicated urinary tract infection due to gram negative pathogens

Exclusion Criteria:

• ileal loops or vesicoureteral reflux

• complete obstruction of any portion of urinary tract, perinephric or intrarenal abscess.

• fungal urinary tract infection

• permanent indirect catheter or nephrostomy unless removed within 48 hours of study entry

• history hypersensitivity to study medication